Life Science investor Forbion raises €2.3 billion
Forbion raises €2.3 billion from Eli Lilly and Company, PGGM, MN, KfW Capital and the Kauffman Foundation.
With two new funds, Forbion aims to finance approximately thirty promising biotech companies, with the first investments already having been made. Thanks to the new funds, Forbion's assets under management are growing to around €7.5 billion. According to the company, this strengthens its position as Europe's largest specialized life sciences investor.
Investors include Eli Lilly and Company, PGGM, MN, KfW Capital, and the Kauffman Foundation, among others. According to co-founder Sander Slootweg, the fund offers Forbion the opportunity to invest in groundbreaking biotech companies developing new treatments for patients worldwide, precisely in a market with limited availability of growth capital.
